In July 2026, China approved a novel drug targeting a key brain receptor linked to narcolepsy type 1. The drug, developed for adolescents aged 16 and older and adults, became available in China first. It marked a historic milestone: China is no longer a follower in global drug development; it's becoming a major contributor.
09-Sep-2026